HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy
The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.